The company has already been testing the autologous cell therapy, LioCyx-M004, in patients with certain liver cancers.

DNA segments that are naturally excised during immune-cell development can replicate, drive damage at various genomic sites and lead to cancer recurrence. Karla K. Rodgers is in the Department of ...

SINGAPORE and GUANGZHOU, China, Sept. 15, 2025 /PRNewswire/ -- Lion TCR, a clinical-stage biotechnology company pioneering T-cell receptor (TCR)-based therapies, today announced that it has received ...

Researchers have harnessed the power of artificial intelligence to tackle one of the most complex challenges in immunology: ...

In the largest study of its kind, researchers from The University of Texas MD Anderson Cancer Center identified three subgroups of patients with large B-cell lymphoma (LBCL) who have different levels ...

The firm is restructuring to extend its cash runway and focus resources on clinical programs, including a Phase I CAR T-cell trial in kidney cancer.

A paper published in Cell highlights how researchers have leveraged AI-based computational protein design to create a novel synthetic ligand that activates the Notch signaling pathway, a key driver in ...

The Notch signaling pathway plays a pivotal role in determining cell fate, especially in the development and function of T cells. But mimicking this highly mechanical, contact-dependent pathway in the ...

An exciting collaboration between the Ragon Institute and the Jameel Clinic at MIT has achieved a significant milestone in leveraging artificial intelligence (AI) to aid the development of T cell ...

Recent immunology research has unveiled the complex relationship between vitamin D and immune system function. This vital nutrient is involved in the development and function of the immune system, ...